Valproic Acid - ClinicalTrials.gov

A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications

Benvacizumab and temsirolimus in combination with plus valproic acid or cetuximab can be used to establish the maximum tolerated doses and dose-limiting toxicities of therapy with bevacizumab and temsirolimus in combination with plus valproic acid or cetuximab. Patients are treated with temsirolimus intravenously over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22. On days 1-7 and 15-21, patients receive temsirolimus and bevacizumab as in Group I and valproic acid orally daily. Patients in Group I receive temsirolimus and bevacizumab.

Source link: https://clinicaltrials.gov/ct2/show/NCT01552434

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions